ARENA PHARMACEUTICALS INC
ARENA PHARMACEUTICALS INC (ARNA): 6 pipeline candidates · ~13 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.4 months
0% dilution
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for ARENA PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$224.8M
Quarterly Burn
$120.5M
Runway
13.4 mo
Revenue
$54K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Frequently asked questions
How many drug candidates are in ARENA PHARMACEUTICALS INC's pipeline?
ARENA PHARMACEUTICALS INC (ARNA) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARENA PHARMACEUTICALS INC's lead drug candidate?
ARENA PHARMACEUTICALS INC's most advanced tracked candidate is apd418 (Phase 2) for acute heart failure.
What is ARENA PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARENA PHARMACEUTICALS INC has approximately 13.4 months of cash runway.
Who is the CEO of ARENA PHARMACEUTICALS INC?
Arena Pharmaceuticals is the chief executive officer of ARENA PHARMACEUTICALS INC (ARNA).
Get the full picture on ARENA PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.